132 results on '"Lotan Y"'
Search Results
2. The optimal number of induction chemotherapy cycles in cN+ bladder cancer
3. Molecular subtyping for predicting non-organ confined disease and survival outcomes after radical cystectomy in clinical high-grade T1 and T2 bladder cancer patients
4. Efficacy of intravesical nadofaragene firadenovec-vncg for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer: 36-month follow-up from a phase 3 trial
5. A systematic review of upper urinary tract recurrence predictors after radical cystectomy
6. Corrigendum to “Nomogram Predicting Bladder Cancer–specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium” [Eur Urol Focus 2021;7:1347–54]
7. 1775P Prevalence of PD-L1 high expression in advanced urothelial carcinoma (aUC): Results from the PREVAIL prospective cohort study
8. Study EV-104: Phase 1 study of intravesical enfortumab vedotin for treatment of patients with Non-Muscle Invasive Bladder Cancer (NMIBC) (Trial in Progress)
9. A urine-based molecular assay refines the risk stratification of the recent American Urological Association guideline on hematuria
10. Prognostic impact of perioperative circulating levels of Insulin-like growth factor-I (IGF-I) and its binding proteins, IGFBP-2 and IGFBP-3, on disease outcomes after radical cystectomy
11. Quality Metric to Assess Adequacy of Hydrogel Rectal Spacer Placement for Prostate Radiotherapy and Association of Metric Score With Dosimetric and Gastrointestinal Toxicity Outcomes
12. Fibroblast growth factor receptor: A systematic review and meta-analysis of prognostic value and therapeutic options in patients with urothelial bladder carcinoma
13. Accuracy of novel urinary biomarker tests for diagnosis and surveillance of NMIBC: A systematic review, diagnostic test accuracy and network meta-analyses
14. Nomogram Predicting Bladder Cancer–specific Mortality After Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-invasive Bladder Cancer: Results of an International Consortium
15. Significant anti-adenovirus antibody response positively correlates with efficacy in patients treated with nadofaragene firadenovec for high-grade BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
16. Molecular characterization of residual bladder cancer after pembrolizumab
17. PUK8 Water: A Prevention Strategy to Decrease the Economic Burden of Recurrent Cystitis Among Women in the United States of America
18. Subgroup analyses of the phase 3 study of intravesical nadofaragene firadenovec in patients with high-grade, BCG-unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
19. Luminal primary muscle-invasive bladder cancer patients are less likely to benefit from platinum-based neoadjuvant chemotherapy
20. Molecular subtyping and immune-gene signatures identify a subset of clinical T1 high-grade (cT1 HG) and cT2 bladder urothelial carcinoma (UC) as candidates for single-agent immune checkpoint inhibition (ICI)
21. Blue light cystoscopy for detection of invasive bladder tumor: Results from multi-institutional registry
22. Phase I Dose-Escalation Trial of Stereotactic Ablative Body Radiotherapy (SAbR) for Men with High-Risk Prostate Cancer
23. Nomogram predicting bladder cancer specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: results of an international consortium
24. Neoadjuvant chemotherapy plus radical cystectomy versus radical cystectomy alone in clinical T2 bladder cancer patients without hydronephrosis: results from a large multicenter cohort study
25. 756P Molecular subtyping and immune-gene signatures identify a subset of clinical T1 high-grade (cT1 HG) and cT2 bladder urothelial carcinoma (UC) as candidates for single-agent immune checkpoint inhibition (ICI)
26. Pivotal trial of MRI-guided transurethral ultrasound ablation in men with localized prostate cancer: Two-year follow-up
27. Nomogram predicting bladder cancer specific mortality after neoadjuvant chemotherapy and radical cystectomy for muscle-invasive bladder cancer: Results of an international consortium
28. The significance of preoperative serum sodium and hemoglobin in upper tract urothelial carcinoma outcomes: Multi-center validation between China and the United States
29. Discovery of a genomic classifier for predicting clinically aggressive luminal bladder tumors with higher rates of pathological upstaging
30. Prognostic value of the systemic inflammation modified glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration
31. A cost comparison of open versus robotic retroperitoneal lymph node dissection for germ cell tumours
32. Serum microRNA-371a-3p levels predict viable germ cell tumour in chemotherapy-naïve patients undergoing retroperitoneal lymph node dissection
33. SUN-317 ECONOMIC IMPLICATIONS OF INCREASED WATER INTAKE ON COST OF RECURRENT URINARY TRACT INFECTIONS BASED ON RESULTS FROM A RANDOMIZED CLINICAL TRIAL
34. Molecular subtyping reveals luminal bladder tumors have lower rates of pathological upstaging at radical cystectomy
35. Prognostic value of the systemic inflammation modified Glasgow Prognostic Score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration
36. Leveraging a robust patient-derived xenograft platform to characterize predictors for engraftment and oncologic outcomes in renal cell carcinoma patients
37. Pivotal study of MRI-guided transurethral ultrasound ablation in men with localized prostate cancer: Preliminary results
38. Clinical value of cholinesterase in patients treated with radical nephroureterectomy for upper urinary tract carcinoma
39. Molecular characterization of neuroendocrine-like bladder cancer
40. Molecular markers (FGFR3 mutation; p53 and Ki-67 expression) and clinical outcome of radical cystectomy for bladder cancer: A multi-center, multi-laboratory study
41. Classifieur génomique permettant d’identifier de tumeurs à profil génomique neuro-endocrine (« ne-like »)
42. Multi-Institutional Phase 2 Trial of High-Dose Stereotactic Body Radiation Therapy with Temporary Hydrogel Spacer for Low- and Intermediate-Risk Prostate Cancer
43. Decipher test impacts decision-making among patients considering adjuvant and salvage treatment following radical prostatectomy: Interim results from the multicenter prospective PRO-IMPACT study
44. Validation of preoperative thrombocytosis as adverse prognostic factor in advanced bladder cancer (BCA) after radical cystectomy (RC)
45. Validation of a mRNA-based urine test for bladder cancer detection in patients with hematuria
46. Does associated CIS with MIBC impact on neoadjuvant chemotherapy? Results of an International consortium
47. Performance characteristics of a mRNA-based urine test for the detection of bladder cancer recurrence
48. Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international multi-institutional study
49. Preoperative anemia is a predictor of disease recurrence, cancer-specific survival and overall survival in bladder cancer patients: A retrospective study on 4335 radical cystectomies
50. A Genomic Classifier Impacts Treatment Decision Making Among Patients With Biochemical Recurrence After Radical Prostatectomy: Results From the Multicenter Prospective PRO-IMPACT Study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.